Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 7/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | ADIPOR2 | Q86V24 | 1/20 | 0.36 |
| ▸ | ADIPOR1 | Q96A54 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22612430 | 1.00 | ATF4 (0.46) | ATF4MCHR1LMNAHPGDHTT | |
| SCHEMBL22612446 | 0.93 | ATF4 (0.56) | ATF4LMNA | |
| SCHEMBL22612443 | 0.93 | ATF4 (0.56) | ATF4LMNA | |
| SCHEMBL22612385 | 0.88 | LIPE (0.49) | ATF4MCHR1LMNAKMT2AMEN1 | |
| SCHEMBL22612387 | 0.88 | LIPE (0.49) | ATF4MCHR1LMNAKMT2AMEN1 | |
| SCHEMBL22397220 | 0.87 | SMYD3 (0.39) | ATF4MCHR1LMNAHPGDHTT | |
| SCHEMBL22612447 | 0.87 | SMYD3 (0.39) | ATF4MCHR1LMNAHPGDHTT | |
| SCHEMBL22612391 | 0.86 | KMT2A (0.40) | ATF4MCHR1LMNAHPGDHTT | |
| SCHEMBL22612392 | 0.86 | KMT2A (0.40) | ATF4MCHR1LMNAHPGDHTT | |
| SCHEMBL22612410 | 0.85 | ATF4 (0.59) | ATF4MCHR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112218851-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-01-12 | — | — | CN | disclosed |
| US-20200347033-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2020-11-05 | — | — | US | disclosed |
| US-20200347033-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347033-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, IRF3 | ATF4 1/4885MCHR1 2082/4885LMNA 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.